Acacia's Euronext Listing To Help Target Unmet US PONV Market

05 Feb 2018

• By John Davis

Acacia Pharma’s long-term aim, once its go-it-alone US strategy is in hand, is to turn its attention to ex-US partnering possibilities for its lead product for post-operative nausea and vomiting. It will also develop a Phase II candidate for chemotherapy-induced nausea and vomiting.

The Grand Place in Brussels • Source: Shutterstock

Just over a month after the FDA accepted Acacia Pharma Ltd.'s US NDA for its novel post-operative nausea and vomiting (PONV) therapy, Baremsis (a low-dose amisulpride injection), and received a PDUFA date of Oct. 5, 2018, the Cambridge, UK-based company announced on Feb. 5 its intention to launch an initial global offering (IGO) on Euronext in Brussels, to raise new funds to support its US marketing preparations.

"The choice of the Belgium exchange does not reflect anything negative about the UK, but is more a reflection of...